[go: up one dir, main page]

MX2019013801A - Compuestos de citocina inhibidora de macrofagos-1 (mic-1) y usos de estos. - Google Patents

Compuestos de citocina inhibidora de macrofagos-1 (mic-1) y usos de estos.

Info

Publication number
MX2019013801A
MX2019013801A MX2019013801A MX2019013801A MX2019013801A MX 2019013801 A MX2019013801 A MX 2019013801A MX 2019013801 A MX2019013801 A MX 2019013801A MX 2019013801 A MX2019013801 A MX 2019013801A MX 2019013801 A MX2019013801 A MX 2019013801A
Authority
MX
Mexico
Prior art keywords
compounds
mic
amino acid
relates
acid extension
Prior art date
Application number
MX2019013801A
Other languages
English (en)
Inventor
Waldemar Conde Frieboes Kilian
Beck Jørgensen Sebastian
zhang Xujia
Gao Xiang
Guan Hongtao
Thøgersen Henning
Sass-Ørum Kristian
Fogh Iversen Lars
Nørgaard Per
Tage Hansen Kristian
Wang Yi
Wieczorek Birgit
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2019013801A publication Critical patent/MX2019013801A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere a compuestos de MIC-1. Más específicamente se refiere a compuestos que comprenden un polipéptido MIC-1 con una extensión de aminoácidos en el N-terminal y un prolongador en donde la extensión de aminoácidos comprende de 3 a 36 residuos de aminoácidos y donde el polipéptido MIC-1 y la extensión de aminoácidos en el N-terminal juntos tienen un pI calculado menor que 6.5. Los compuestos de la invención tienen actividad de MIC-1. La invención se refiere, además, a composiciones farmacéuticas que comprenden tales compuestos y excipientes farmacéuticamente aceptables, así como también al uso médico de los compuestos.
MX2019013801A 2017-05-23 2018-05-23 Compuestos de citocina inhibidora de macrofagos-1 (mic-1) y usos de estos. MX2019013801A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017085576 2017-05-23
CN2017113335 2017-11-28
PCT/EP2018/063476 WO2018215525A1 (en) 2017-05-23 2018-05-23 Mic-1 compounds and uses thereof

Publications (1)

Publication Number Publication Date
MX2019013801A true MX2019013801A (es) 2020-01-30

Family

ID=62567604

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013801A MX2019013801A (es) 2017-05-23 2018-05-23 Compuestos de citocina inhibidora de macrofagos-1 (mic-1) y usos de estos.

Country Status (17)

Country Link
US (3) US10398782B2 (es)
EP (1) EP3630805A1 (es)
JP (1) JP7015322B2 (es)
KR (1) KR20200010353A (es)
CN (1) CN111183148A (es)
AU (1) AU2018272911B2 (es)
BR (1) BR112019024102A2 (es)
CA (1) CA3064320A1 (es)
CL (1) CL2019003441A1 (es)
CO (1) CO2019013768A2 (es)
MA (1) MA48956A (es)
MX (1) MX2019013801A (es)
PE (1) PE20200514A1 (es)
PH (1) PH12019550241A1 (es)
RU (1) RU2019141031A (es)
TW (1) TWI710377B (es)
WO (1) WO2018215525A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
TW201741333A (zh) 2016-05-24 2017-12-01 諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
TWI710377B (zh) * 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
JP7539902B2 (ja) 2018-10-22 2024-08-26 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー グルカゴン様ペプチド１（ｇｌｐ１）－増殖分化因子１５（ｇｄｆ１５）融合タンパク質及びその使用
WO2021067655A1 (en) 2019-10-04 2021-04-08 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
WO2021136223A1 (en) * 2019-12-31 2021-07-08 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
CN114729060B (zh) 2020-09-30 2022-11-25 北京质肽生物医药科技有限公司 多肽缀合物和使用方法
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
KR20240163717A (ko) 2022-03-30 2024-11-19 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 폴리펩티드 접합체의 액체 약학 조성물 및 그의 사용 방법

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001077137A1 (en) 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
CN1241946C (zh) 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
DK2441466T3 (da) 2004-04-13 2014-10-27 St Vincents Hosp Sydney MIC-1-inhiberende middel
US20050256576A1 (en) 2004-05-13 2005-11-17 Moskowitz Nathan C Artificial expansile total lumbar and thoracic discs for posterior placement without supplemental instrumentation and its adaptation for anterior placement of artificial cervical, thoracic and lumbar discs
DK1751184T3 (da) 2004-05-13 2009-11-23 Lilly Co Eli FGF-21 fusionsproteiner
EP1771467A2 (en) 2004-07-26 2007-04-11 Asterion Limited Linkers
ES2531372T3 (es) 2006-10-13 2015-03-13 Novo Nordisk Healthcare Ag Enzimas de procesamiento fusionadas a marcadores de proteínas básicas
CN103298935A (zh) 2007-08-15 2013-09-11 阿穆尼克斯公司 用于改善生物活性多肽性能的组合物和方法
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
CN102149411A (zh) 2008-09-12 2011-08-10 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
RU2525393C2 (ru) * 2009-01-23 2014-08-10 Ново Нордиск А/С Производные fgf21 со связующим альбумина а-в-с-d-e- и их применение
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
EA020843B1 (ru) * 2009-02-03 2015-02-27 Амуникс Оперейтинг Инк. Удлиненные рекомбинантные полипептиды и содержащие их композиции
US10752664B2 (en) 2011-04-08 2020-08-25 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
BR112014018575A2 (pt) 2012-01-26 2017-07-04 Amgen Inc polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
US9550819B2 (en) * 2012-03-27 2017-01-24 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
CA2899170C (en) 2013-01-30 2022-08-02 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
MX369152B (es) 2013-07-31 2019-10-30 Amgen Inc Construcciones del factor de diferenciación de crecimiento 15 (gdf-15).
EP3036262A4 (en) 2013-08-22 2017-03-01 Acceleron Pharma Inc. Tgf-beta receptor type ii variants and uses thereof
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
RU2017101436A (ru) 2014-06-24 2018-07-24 Ново Нордиск А/С Mic-1 слитные белки и их применение
DK3236991T3 (da) * 2014-12-23 2019-08-26 Novo Nordisk As Fgf21-derivater og anvendelser deraf
MA41794A (fr) * 2015-03-18 2018-01-23 The California Institute For Biomedical Res Agents thérapeutiques modifiés et compositions associées
GB201517528D0 (en) 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
EA201890850A1 (ru) 2015-10-02 2018-09-28 Юлиус-Максимилианс-Универзитет Вюрцбург Комбинированное лечение с использованием ингибиторов человеческого фактора роста и дифференцировки 15 (gdf-15) и блокаторов контрольных точек иммунного ответа
ES2968226T3 (es) 2015-10-02 2024-05-08 Univ Wuerzburg J Maximilians GDF-15 como marcador de diagnóstico para predecir la evolución clínica de un tratamiento con bloqueadores de puntos de control inmunitario
WO2017109706A1 (en) 2015-12-22 2017-06-29 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
TW201741333A (zh) 2016-05-24 2017-12-01 諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途

Also Published As

Publication number Publication date
JP2020520918A (ja) 2020-07-16
US20230364248A1 (en) 2023-11-16
CO2019013768A2 (es) 2020-04-01
JP7015322B2 (ja) 2022-02-02
KR20200010353A (ko) 2020-01-30
WO2018215525A1 (en) 2018-11-29
MA48956A (fr) 2020-04-08
RU2019141031A (ru) 2021-06-16
CA3064320A1 (en) 2018-11-29
US20180339057A1 (en) 2018-11-29
BR112019024102A2 (pt) 2020-06-02
RU2019141031A3 (es) 2021-07-16
WO2018215525A8 (en) 2020-01-02
TWI710377B (zh) 2020-11-21
PE20200514A1 (es) 2020-03-05
US10398782B2 (en) 2019-09-03
TW201900219A (zh) 2019-01-01
CL2019003441A1 (es) 2020-05-08
AU2018272911A1 (en) 2019-12-19
PH12019550241A1 (en) 2020-12-07
US20200079829A1 (en) 2020-03-12
AU2018272911B2 (en) 2022-09-08
CN111183148A (zh) 2020-05-19
EP3630805A1 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
PH12019550241A1 (en) Mic-1 compounds and uses thereof
PH12018502465A1 (en) Mic-1 compounds and use thereof
TW201613958A (en) MIC-1 fusion proteins and uses thereof
EP4299118A3 (en) Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
MY187047A (en) Selective pyy compounds and uses thereof
PH12020550051A1 (en) Glp-1 compositions and uses thereof
WO2015191781A3 (en) Apelin polypeptides
MY161773A (en) Amylin analogues and pharmaceutical compositions thereof
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
WO2020123795A3 (en) Anellosomes for delivering protein replacement therapeutic modalities
WO2017093810A3 (en) Composition for intraoral delivery of biologically active peptides and proteins
PH12021552741A1 (en) Solid forms of a glyt1 inhibitor
MY205028A (en) Protein for treatment of inflammatory diseases
CR20220206A (es) Agonistas del receptor npy2
EP4653537A3 (en) Rhodopsin gene therapy for regenerating visual function or for preventing deterioration in visual function
PH12021550122A1 (en) Solubilized apyrases, methods and use
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
MX362058B (es) Péptido pntx(19) sintético, composición farmacéutica y uso.
MX2020013684A (es) Formulaciones/composiciones que comprenden ibrutinib.
WO2018200814A3 (en) Modified cyclic peptides and therapeutic use thereof
MX2019001153A (es) Peptidos ciclicos como antagonistas del receptor c5a.
WO2012102625A3 (en) Therapeutic composition
WO2015150468A3 (en) Novel ifn beta protein analogs
PH12017501918A1 (en) Multi-peptide composition
MX2020008295A (es) Polipeptidos, composiciones y sus usos.